Guaili Wu

This inventor holds 15 USPTO granted patents and 2 published patent applications, plus 7 CIPO patents and 11 EPO patents. Top assignees: Jiangsu Hengrui Medicine Company Ltd., Jiangsu Hengrui Co., Ltd.. Active years: 2016-2021.

USPTO Granted Patents = 15 (Patent Applications = 2)

% Patents Active = 66.7

CIPO Patents = 7 (Patent Applications = 6)

EPO Patents = 11 (Patent Applications = 13)

Average Co-Inventor Count = 3.8

ph-index = 3

Forward Citations = 25(Granted Patents)

Company Filing History:

14 out of 159

Jiangsu Hengrui Medicine Company Ltd.

patents

1 out of 1

Jiangsu Hengrui Co., Ltd.

patent

Years Active: 2016-2021

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11198683 - Method for preparing tyrosine kinase inhibitor and derivative thereof (2021-12-14),

2. 11059810 - Pharmaceutically acceptable salt as renal outer medullary potassium channel inhibitor (2021-07-13),

3. 10793548 - Method for preparing tyrosine kinase inhibitor and derivative thereof (2020-10-06),

4. 10626116 - Crystalline form of BTK kinase inhibitor and preparation method thereof (2020-04-21),

5. 10358424 - Sodium salt of uric acid transporter inhibitor and crystalline form thereof (2019-07-23),

6. 10301344 - L-proline complex of sodium-glucose cotransporter 2 inhibitor, monohydrate and crystal form thereof (2019-05-28),

7. 10196361 - Sodium salt of uric acid transporter inhibitor and crystalline form thereof (2019-02-05),

8. 10160759 - Hydroxyethyl sulfonate of cyclin-dependent protein kinase inhibitor, crystalline form thereof and preparation method therefor (2018-12-25),

9. 10150770 - Crystal form of bisulfate of JAK inhibitor and preparation method therefor (2018-12-11),

10. 10150739 - Crystalline form of androgen receptor inhibitor and preparation method thereof (2018-12-11),

11. 10118911 - P-toluenesulfonate for MEK kinase inhibitor, and crystal form thereof and preparation method therefor (2018-11-06),

12. 10030018 - Hydroxyethyl sulfonate of cyclin-dependent protein kinase inhibitor, crystalline form thereof and preparation method therefor (2018-07-24),

13. 10023577 - Crystalline form of JAK kinase inhibitor bisulfate and a preparation method thereof (2018-07-17),

14. 9422300 - Bisulfate of janus kinase (JAK) inhibitor and preparation method therefor (2016-08-23),

15. 9309226 - Crystalline form I of tyrosine kinase inhibitor dimaleate and preparation methods thereof (2016-04-12),

Title: Guaili Wu: Innovator in Pharmaceutical Chemistry

Introduction

Guaili Wu is a prominent inventor based in Jiangsu, China, known for his significant contributions to pharmaceutical chemistry. With a total of 15 patents to his name, he has made remarkable advancements in the field of drug development.

Latest Patents

Among his latest patents is a method for preparing a tyrosine kinase inhibitor and its derivatives. This innovative method features a short synthesis route, low costs, and easy operation, making it suitable for large-scale production. Another notable patent involves a pharmaceutically acceptable salt as a renal outer medullary potassium channel (ROMK) inhibitor. Specifically, this patent describes an L-tartrate and its crystal forms, which have shown improved bioavailability and stability.

Career Highlights

Guaili Wu has worked with reputable companies such as Jiangsu Hengrui Medicine Company Ltd. and Jiangsu Hengrui Co., Ltd. His work in these organizations has been instrumental in advancing pharmaceutical research and development.

Collaborations

Throughout his career, Guaili Wu has collaborated with notable colleagues, including Piaoyang Sun and Xiaohui Gao. These partnerships have contributed to the success of his innovative projects.

Conclusion

Guaili Wu's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as a leading inventor in the industry. His work continues to influence the development of effective medical treatments.